{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', '1.2.', 'Schema', 'Figure 1', 'Study Schematic', 'Screening Period', 'Randomized Phase', 'Continuation Phase', '(up to 28 days)', '(Day 1 to Week 52)', 'DTG/3TC FDC', 'DTG/3TCFDC', 'HIV-infected, ART-experienced', 'adults', '. 2 3 months on uninterrupted CAR', '(2 NRTIs + INI, NNRTI or PI)', 'HIV-1 RNA <50 c/mL', 'CAR', 'Day 1', 'Week 24', 'Week 48', 'Week 52', '(1:1 randomization)', 'Primary', 'Enppoint', 'Note: The Continuation Phase is not applicable for participants in Sweden and Denmark.', '15']['2017N331008_06', 'CONFIDENTIAL', '208090', '1.3.', 'Schedule of Activities (SoA)', 'Procedures', 'Randomized Phase', 'Continuation', 'Phase', 'Every 12', 'Weeks', '4', '12', '24', '36', '48b', '52', 'After', 'Week 52', 'Clinical and Other Assessments', 'Written informed consent', 'X', 'Inclusion/Exclusion criteriae', 'X', 'Demography', 'X', 'Prior ART history', 'Medical history', 'X', 'Menopause historyg', 'X', 'X', 'Current medical conditions', 'Cardiovascular risk assessment including', 'vital signsh', 'Body Weight (BMI will be calculated within', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'the eCRF)i', 'HIV risk factors and mode of transmission', 'X', 'CDC HIV-1 classification', 'X', 'X', 'HIV associated conditionsi', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Columbia Suicidality Severity Rating Scale', 'X', 'X', 'X', 'X', 'X', 'X', 'Concomitant medication', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Symptom Directed Physical Exam', 'X', 'X', 'X', 'X', 'X', '12-lead ECGm', 'Adverse events', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Serious adverse events', 'Xn', 'X', 'X', 'X', 'X', '16']['2017N331008_06', 'CONFIDENTIAL', '208090', 'Procedures', 'Randomized Phase', 'Continuation', 'Phasec', 'Every 12', 'Weeks', '4', '12', '24', '36', '48b', '52', 'After', 'Week 52', 'Willingness to Switch\u00b0', 'X\u00b0', 'HIV TSQP', 'X', 'X', 'X', 'Symptom Distress Modulep', 'X', 'X', 'X', 'X (every 24 weeks)', 'Laboratory Assessments', 'Quantitative plasma HIV-1 RNAq', 'X', 'X', 'X', 'X', 'X', 'X', 'Lymphocyte subset', 'X', 'X', 'X', 'X', 'Plasma for storages', 'X', 'X', 'X', 'X', 'X', 'X', 'Clinical chemistryt', 'X', 'X', 'X', 'X', 'Hematology', 'X', 'X', 'X', 'X', 'PT/INR (for Child-Pugh)', 'Fasting lipids and glucoseu', 'X', 'X', 'Xv', 'Urinalysis and spot urine for protein', 'X', 'X', 'X', 'X', 'analysisw', 'Pregnancy testx,y', 'S', 'U/Sz', 'S', 'S', 'S', 'S', 'S', 'S', 'S', 'S', 'HBsAg, anti-HBc, Anti-HBs, and HBV', 'X', 'DNAaa', 'HCV antibody', 'X', 'RPR', 'Renal, bone and inflammatory marker', 'X', 'X', 'X', 'X', 'analytes (blood/urine) and HbA1c, insulin', 'and glucosebb', 'Whole Blood (Virology) CC', 'X', 'X', 'X', 'Whole Blood (Telomere Length)dd', 'X', 'Xee', '17']\n\n###\n\n", "completion": "END"}